QuadraMed acquisition: Investigation against directors

Law Offices of Howard G. Smith announces that it is investigating potential claims against the Board of Directors of QuadraMed Corp. ("QuadraMed" or the "Company") (NASDAQ: QDHC) arising from the Company's announcement of its intent to be acquired by Francisco Partners.

On December 8, 2009, the companies announced that Francisco Partners will acquire QuadraMed in an all-cash transaction valued at $126 million. According to the agreement, shareholders will receive $8.50 per share for QDHC common stock and $13.7097 per share of Series A Cumulative Mandatory Convertible Preferred Stock. The investigation is focused on the potential unfairness of the price to QuadraMed shareholders and the process by which the QuadraMed Board of Directors considered and approved the transaction.

If you own shares of QuadraMed, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at 215-638-4847, Toll Free at 888-638-4847, or visit www.howardsmithlaw.com. You may also email my firm at [email protected].

Posted in:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.